Mizuki Y, Ushijima I, Yamada M, Tanaka M, Inanaga K
Int Clin Psychopharmacol. 1986 Oct;1(4):303-13. doi: 10.1097/00004850-198610000-00004.
Clinical prospects of an analog of thyrotropin-releasing hormone (DN-1417) and des-tyrosine-gamma-endorphin (DT gamma E) in schizophrenia were examined by using the Brief Psychiatric Rating Scale (BPRS) and the electroencephalogram (EEG). Twelve inpatients with chronic schizophrenia were administered fixed doses of neuroleptics throughout the study. Six patients were treated with DN-1417 (DN-1417 group), and the remaining 6 patients with DT gamma E (DY gamma E group). One mg/day of DN-1417 or DT gamma E was given intramuscularly for 2 consecutive weeks followed by 1 week of no drug treatment. In the DN-1417 group, both total BPRS scores and scores on hallucinatory behaviour and unusual thought content decreased in the first and third weeks. The power values of alpha and beta activities from the frontal area increased in the first and third weeks, whereas an increase in alpha activity and a decrease of high-fast beta activity from the occipital area were obtained during the study. On the other hand, the DT gamma E group failed to show either a decrease in BPRS scores or any remarkable EEG changes except for a slight decrease in beta activity. These results suggest that the positive symptoms of schizophrenia are improved by DN-1417 treatment, and that the alterations in BPRS scores coincide with changes in the frontal EEG.
采用简明精神病评定量表（BPRS）和脑电图（EEG）对促甲状腺激素释放激素类似物（DN - 1417）和去酪氨酸γ-内啡肽（DTγE）在精神分裂症中的临床前景进行了研究。在整个研究过程中，12例慢性精神分裂症住院患者接受了固定剂量的抗精神病药物治疗。6例患者接受DN - 1417治疗（DN - 1417组），其余6例患者接受DTγE治疗（DTγE组）。连续2周每周肌肉注射1mg/天的DN - 1417或DTγE，随后停药1周。在DN - 1417组中，第一周和第三周BPRS总分以及幻觉行为和异常思维内容得分均下降。额叶区域α和β活动的功率值在第一周和第三周增加，而在研究期间枕叶区域α活动增加，高快β活动减少。另一方面，DTγE组除β活动略有下降外，BPRS得分未下降，EEG也无明显变化。这些结果表明，DN - 1417治疗可改善精神分裂症的阳性症状，且BPRS得分的变化与额叶脑电图的变化一致。
